xpro1595
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03943264)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Brain Diseases · Phase 2
- Central Nervous System Diseases · Phase 2
- Cognition Disorders · Phase 2
- Cognitive Dysfunction · Phase 2
- COVID-19 · Phase 2
- Dementia · Phase 2
- Mental Disorders · Phase 2
- Nervous System Diseases · Phase 2
- Neurocognitive Disorders · Phase 2
- Neurodegenerative Diseases · Phase 2
- Tauopathies · Phase 2
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05522387 | Phase 2 | Nov 30, 2022 | Inmune Bio, Inc. |
| NCT05321498 | Phase 2 | Sep 30, 2022 | Inmune Bio, Inc. |
| NCT05318976 | Phase 2 | Feb 28, 2022 | Inmune Bio, Inc. |
| NCT04370236 | Phase 2 | Jun 30, 2020 | Inmune Bio, Inc. |
| NCT03943264 | Phase 1 | Jun 30, 2019 | Alzheimer's Association, Inmune Bio, Inc., Monash University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inmune Bio, Inc. | For profit | 5 | 5 | 2 | 2019 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1